

# ISPOR Real-World Evidence Summit 2025

*Through the Lens of Asia Pacific*  
28-30 September 2025 | Tokyo, Japan



## Panel Discussion Framework

Title: The Promise of OMOP and Database Research at Scale in APAC: Opportunities and Gaps has been

Key Topics: 3 core themes

1. Adoption
2. Trust and Reliability
3. Multi-center collaboration

# Panel Composition

## ISPOR Real-World Evidence Summit 2025

*Through the Lens of Asia Pacific*  
28-30 September 2025 | Tokyo, Japan



Moderator: **Sven Demiya**, Ph.D., MBA Sr  
Director & Head  
RWE/HEOR & PH IQVIA  
Solutions G.K. Japan



Industry Global:  
**Mui Van Zandt**  
VP/ Global Head Data  
Strategy  
IQVIA Inc. US



Academic expertise:  
Prof. **Jason C. Hsu**,  
Ph.D. – Taipei Medical  
University.



Panelists: 3 experts with  
diverse perspectives

Industry Local:

**Saaya Tsutsu  , Ph.D**

J&J Innovative Medicine

Integrated Market Access  
Team (IMAT)

Value Evidence & Access  
Head

Janssen Pharmaceutical  
K.K.



# History of OMOP/OHDSI



## End of OMOP Experiment

**Main findings in OMOP experiment**

- Heterogeneity in estimates due to choice of database
- Heterogeneity in estimates due to analysis choices
- Except little heterogeneity due to outcome definitions
- Good performance (AUC > 0.7) in distinguishing positive from negative controls for optimal methods when stratifying by outcome and restricting to powered test cases
- Self controlled methods perform best for all outcomes

**First OHDSI Symposium/  
Network Study Published**

**First Hackathon  
at Columbia University**

**European Chapter**

**FDA Adoption  
(FDA BEST Launch)**

**Australia, Japan Chapters**

**India Chapter**

2013

2015

2017

2019

2022

2009

2014

2016

2018

2020

2023

**OMOP Experiment #1**

**Launch of OHDSI**

**China Chapter**

**EHDEN Initiation (Europe)**

**OHDSI COVID-19  
Study-a-Thon**

**OMOP in Thailand**

**OMOP Experiment 1 (2009-2010)**

• Open source  
• Standards-based  
• Common Data Model

• 10 data sources  
• Claims and EHRs  
• 200M+ lives

• 16 methods  
• Epidemiology designs  
• Statistical approaches adapted for longitudinal data

A diagram showing the components of OMOP Experiment 1, including data sources, methods, and a heatmap of results.

**Korea Chapter**



**FEEDER-NET Initiation (Korea)**

**First European Symposium**

**Singapore, Taiwan Chapters**




**Thailand (1)  
Siriraj Hospital EHR**

# OMOP common data model (CDM)

*Ontologies are critical when designing at data models*

ISPOR Real-World Evidence  
Summit 2025


Through the Lens of Asia Pacific  
28-30 September 2025 | Tokyo, Japan



- **10,088,289 concepts**
  - 3,533,508 standard concepts
  - 752,175 classification concepts
- **134 vocabularies**
- **40 domains**

# ISPOR Real-World Evidence Summit 2025

Through the Lens of Asia Pacific  
28-30 September 2025 | Tokyo, Japan





# Scientific Impact of OMOP studies

ISPD World Evidence Summit 2023

Characterization

Estimation

Prediction

Clinical Epidemiology

Open Access Full Text Article

Unraveling COVID-19: A Large-Scale Characterization Using CHARY

Clinical Epidemiology

Open Access Full Text Article

Unraveling COVID-19: A Large-Scale Characterization Using CHARY

RHEUMATOLOGY

Issues More Content Submit Purchase

PDS Pharmacoeconomics & Drug Safety

JCO® Clinical Oncology An American Society

Dovepress

open access to scientific and medical research

ORIGINAL RESEARCH

International Journal of Obesity

Explore content About the journal

nature

Article |

Epidemiology and Public Health

Charlottesville State

Martina F.

Ahmed, H.

Dalia Dav

Gong, L.

Morales.

Home >

FREE RESEARCH

Articles

Risk of

the COVID-19

USA: a

Hui-Lee Wor

Kandace L. A

Cheryl N. Mc

Rachel P. Ogi

Zhiruo Wan

Yoganand Ch

Steven A. And

Kristine Ly

Daniel R. Morales

Mitchell M. Conover

Seng Chan You

> Ann Intern Med. 2022 Nov;175(11):1515-1524. doi: 10.7326/M22-0511. Epub 2022 Nov 1.

FULL TEXT LINKS

Annals FULL TEXT

ACTIONS

Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban

> Ann Intern Med. 2022 Nov;175(11):1515-1524. doi: 10.7326/M22-0511. Epub 2022 Nov 1.

FULL TEXT LINKS

Annals FULL TEXT

Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban

> JAMA Netw Open. 2022 Mar 1;5(3):e223877. doi: 10.1001/jamanetworkopen.2022.3877.

FULL TEXT LINKS

JAMA Network Open FULL TEXT

FREE Fulltext PMC

Analysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort

Meta-Analysis > BMJ. 2022 Oct 26;379:e071594. doi: 10.1136/bmj-2022-071594.

FULL TEXT LINKS

Comparative risk of thrombocytopenic events associated with international normalized ratio European count

Xintong Li<sup>1</sup>, Edward Burn<sup>2</sup>, Antonella Delmestri<sup>1</sup>, Katia V Mees Mosseveld<sup>5</sup>, Luis H Joh Catherine Cohet<sup>9</sup>, Victoria St

Predi

depre

obser

Anastasiya Nestsiarovich, Jenna M. Reps, Michael

Beaton, Xinzhuo Jiang, Matthew Spotnitz, Steph

G. Reich, Dong Yun Lee, Sang Joon Son, Seng Chan You, Rae Woong Park, Patrick B. Ryan & Christophe

G. Lambert

AAP Publications

Search...

PEDIATRICS®

Content

Authors/Reviewers

Collections

Multimedia

Blogs

Volume 148, Issue 3  
September 2021

ARTICLES | SEPTEMBER 01 2021

Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience

Talita Duarte-Salles, PhD; David Vizcaya, PhD; Andrea Pistillo, MSc; Paula Casajust, MSc; Anthony G. Sena, BA; Lana Yin Hui Lai, PhD; Albert Prats-Urbe, MD; Waheed-UI-Rahman Ahmed, PhD; Tamir M. Alshammari, PhD; Heba Alghoul, PhD; Osaid Alser, PhD; Edward Burn, PhD; Seng Chan You, PhD; Carlos Areia, PhD; Clair Blacketer, MPH; Scott DuVall, PhD; Thomas Falconer, MSc; Sergio Fernandez-Bertolin, BSc; Stephen Fortin, PhD; Asieh Golozar, PhD; Mengchun Gong, PhD; Eng Hooi Tan, PhD; Vojtech Huser, PhD; Pablo Iveli, PhD; Daniel R. Morales, PhD; Fredrik Nyberg, PhD; Jose D. Posada, PhD; Martina Recalde, MPH; Elena Roel, MD; Lisa M. Schilling, PhD; Nigam H. Shah, PhD; Karishma Shah, PhD; Marc A. Suchard, PhD; Lin Zhang, PhD; Ying Zhang, PhD; Andrew E. Williams, PhD; Christian G. Reich, PhD; George Hripsak, PhD; Peter Rijnbeek, PhD; Patrick Ryan, PhD; Kristin Kostka, MPH; Daniel Prieto-Alhambra, PhD